Loading…
Vitals RX was cited for unlawfully selling unapproved and misbranded compounded drugs, specifically semaglutide and tirzepatide products, over the internet to U.S. consumers. The company's website marketing claimed "Semaglutide/Tirzepatide/Ozempic Weight Loss Clinic," falsely implying its compounded products were equivalent to FDA-approved drugs, violating the Federal Food, Drug, and Cosmetic Act sections 502(a) and 502(bb). The FDA determined these products were misbranded because compounded drugs are not FDA-approved, and the company's claims created a misleading impression that its products held the same status as approved alternatives.